205 related articles for article (PubMed ID: 24219689)
1. Low- and high-grade bladder cancer determination via human serum-based metabolomics approach.
Bansal N; Gupta A; Mitash N; Shakya PS; Mandhani A; Mahdi AA; Sankhwar SN; Mandal SK
J Proteome Res; 2013 Dec; 12(12):5839-50. PubMed ID: 24219689
[TBL] [Abstract][Full Text] [Related]
2. Low- and high-grade bladder cancer appraisal via serum-based proteomics approach.
Bansal N; Gupta A; Sankhwar SN; Mahdi AA
Clin Chim Acta; 2014 Sep; 436():97-103. PubMed ID: 24875752
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive urinary metabonomic diagnosis of human bladder cancer.
Pasikanti KK; Esuvaranathan K; Ho PC; Mahendran R; Kamaraj R; Wu QH; Chiong E; Chan EC
J Proteome Res; 2010 Jun; 9(6):2988-95. PubMed ID: 20337499
[TBL] [Abstract][Full Text] [Related]
4. Metabolomics-derived prostate cancer biomarkers: fact or fiction?
Kumar D; Gupta A; Mandhani A; Sankhwar SN
J Proteome Res; 2015 Mar; 14(3):1455-64. PubMed ID: 25609016
[TBL] [Abstract][Full Text] [Related]
5. Three serum metabolite signatures for diagnosing low-grade and high-grade bladder cancer.
Tan G; Wang H; Yuan J; Qin W; Dong X; Wu H; Meng P
Sci Rep; 2017 Apr; 7():46176. PubMed ID: 28382976
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic ductal adenocarcinoma is associated with a distinct urinary metabolomic signature.
Davis VW; Schiller DE; Eurich D; Bathe OF; Sawyer MB
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S415-23. PubMed ID: 23096698
[TBL] [Abstract][Full Text] [Related]
7. Urinary metabotyping of bladder cancer using two-dimensional gas chromatography time-of-flight mass spectrometry.
Pasikanti KK; Esuvaranathan K; Hong Y; Ho PC; Mahendran R; Raman Nee Mani L; Chiong E; Chan EC
J Proteome Res; 2013 Sep; 12(9):3865-73. PubMed ID: 23885889
[TBL] [Abstract][Full Text] [Related]
8. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS).
Chan EC; Koh PK; Mal M; Cheah PY; Eu KW; Backshall A; Cavill R; Nicholson JK; Keun HC
J Proteome Res; 2009 Jan; 8(1):352-61. PubMed ID: 19063642
[TBL] [Abstract][Full Text] [Related]
9. Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of urine.
Carrola J; Rocha CM; Barros AS; Gil AM; Goodfellow BJ; Carreira IM; Bernardo J; Gomes A; Sousa V; Carvalho L; Duarte IF
J Proteome Res; 2011 Jan; 10(1):221-30. PubMed ID: 21058631
[TBL] [Abstract][Full Text] [Related]
10. ¹H NMR-derived serum metabolomics of leukoplakia and squamous cell carcinoma.
Gupta A; Gupta S; Mahdi AA
Clin Chim Acta; 2015 Feb; 441():47-55. PubMed ID: 25499120
[TBL] [Abstract][Full Text] [Related]
11. FTIR spectroscopy of biofluids revisited: an automated approach to spectral biomarker identification.
Ollesch J; Drees SL; Heise HM; Behrens T; Brüning T; Gerwert K
Analyst; 2013 Jul; 138(14):4092-102. PubMed ID: 23712384
[TBL] [Abstract][Full Text] [Related]
12. LC-MS-based serum metabolic profiling for genitourinary cancer classification and cancer type-specific biomarker discovery.
Lin L; Huang Z; Gao Y; Chen Y; Hang W; Xing J; Yan X
Proteomics; 2012 Aug; 12(14):2238-46. PubMed ID: 22685041
[TBL] [Abstract][Full Text] [Related]
13. NMR-derived targeted serum metabolic biomarkers appraisal of bladder cancer: A pre- and post-operative evaluation.
Gupta A; Bansal N; Mitash N; Kumar D; Kumar M; Sankhwar SN; Mandhani A; Singh UP
J Pharm Biomed Anal; 2020 May; 183():113134. PubMed ID: 32070930
[TBL] [Abstract][Full Text] [Related]
14. [Proton nuclear magnetic resonance spectroscopy recognition of metabolic patterns in fecal extracts for early diagnosis of colorectal cancer].
Lin Y; Wang ZN; Ma CC; Liu CK; Yang JR; Shen ZW; Wu RH
Zhonghua Yu Fang Yi Xue Za Zhi; 2016 Sep; 50(9):788-793. PubMed ID: 27655598
[No Abstract] [Full Text] [Related]
15. ¹H NMR-based metabolomic study of metabolic profiling for systemic lupus erythematosus.
Ouyang X; Dai Y; Wen JL; Wang LX
Lupus; 2011 Nov; 20(13):1411-20. PubMed ID: 21976403
[TBL] [Abstract][Full Text] [Related]
16. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
17. Prospective evaluation of fluorescence-in situ-hybridization to detect bladder cancer: results from the UroScreen-Study.
Banek S; Schwentner C; Täger D; Pesch B; Nasterlack M; Leng G; Gawrych K; Bonberg N; Johnen G; Kluckert M; Gakis G; Todenhöfer T; Hennenlotter J; Brüning T; Stenzl A;
Urol Oncol; 2013 Nov; 31(8):1656-62. PubMed ID: 22621963
[TBL] [Abstract][Full Text] [Related]
18. Discovery and validation of potential urinary biomarkers for bladder cancer diagnosis using a pseudotargeted GC-MS metabolomics method.
Zhou Y; Song R; Ma C; Zhou L; Liu X; Yin P; Zhang Z; Sun Y; Xu C; Lu X; Xu G
Oncotarget; 2017 Mar; 8(13):20719-20728. PubMed ID: 28157703
[TBL] [Abstract][Full Text] [Related]
19. Nuclear matrix protein 22 for bladder cancer detection: comparative analysis of the BladderChek® and ELISA.
Hatzichristodoulou G; Kübler H; Schwaibold H; Wagenpfeil S; Eibauer C; Hofer C; Gschwend J; Treiber U
Anticancer Res; 2012 Nov; 32(11):5093-7. PubMed ID: 23155286
[TBL] [Abstract][Full Text] [Related]
20. Broad identification of bacterial type in urinary tract infection using (1)h NMR spectroscopy.
Gupta A; Dwivedi M; Mahdi AA; Khetrapal CL; Bhandari M
J Proteome Res; 2012 Mar; 11(3):1844-54. PubMed ID: 22292465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
